Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by 1832 Asset Management L.P.

1832 Asset Management L.P. lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 337,638 shares of the medical equipment provider’s stock after purchasing an additional 22,354 shares during the quarter. 1832 Asset Management L.P.’s holdings in Intuitive Surgical were worth $150,198,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently modified their holdings of ISRG. Ridgewood Investments LLC purchased a new position in Intuitive Surgical during the second quarter valued at approximately $26,000. Creekmur Asset Management LLC raised its position in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. LGT Financial Advisors LLC raised its position in Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 54 shares in the last quarter. Delos Wealth Advisors LLC raised its position in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Finally, LRI Investments LLC purchased a new position in Intuitive Surgical during the first quarter valued at approximately $30,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now owns 295 shares in the company, valued at $145,113.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,120 shares of company stock valued at $25,528,753. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $486.20 on Friday. The stock’s fifty day moving average is $468.01 and its two-hundred day moving average is $425.12. The firm has a market capitalization of $172.46 billion, a P/E ratio of 87.76, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.18 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Barclays lifted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Citigroup lifted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Robert W. Baird boosted their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Evercore ISI cut their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, BTIG Research boosted their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.